Cullinan Therapeutics will present interim Phase 3 REZILIENT3 data at WCLC26. The study is testing first line zipalertinib plus chemotherapy, a key update for its lung cancer strategy with partner Taiho.
published
Cullinan Therapeutics will present interim Phase 3 REZILIENT3 data at WCLC26. The study is testing first line zipalertinib plus chemotherapy, a key update for its lung cancer strategy with partner Taiho.
Latest documented BWB result
$META market result
I sold the $META $655 Puts 9/25 for $7.60
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.